Compare Amphastar Pharmaceuticals Inc (AMPH) vs Cloudflare Inc (NET) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Cloudflare (NET) trades at $268.40, down 2.61% over 24 hours but remains near recent highs. The stock shows strong technical momentum with bullish moving averages and recent analyst upgrades. Fundamentally, revenue grew to $2.17 billion in 2025, though net income remains negative at -$102 million. Recent news highlights Cloudflare's strategic pivot toward AI infrastructure, including a research pilot with OpenAI announced July 8, 2026.

Outlook remains optimistic due to AI-driven growth potential and consistent earnings beats, but high valuation multiples (P/S 40.36) and negative profitability pose risks. Analyst consensus is strongly bullish with a $250.33 price target, though competition and execution challenges could pressure shareholder returns.